Overexpression of hexokinase-2 in giant cell tumor of bone is associated with false positive in bone tumor on FDG-PET/CT

Archives of Orthopaedic and Trauma Surgery

Volumn 132, Issue 11, 2012, Pages 1561-1568

  Hoshi, Manabu ^a   Takada, Jun ^a   Oebisu, Naoto ^a   Hata, Kanako ^a   Ieguchi, Makoto ^a   Nakamura, Hiroaki ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Bone tumor; FDG PET CT; Giant cell tumor of bone; Hexokinase 2

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; HEXOKINASE; HEXOKINASE 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE METASTASIS; CHILD; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ENCHONDROMA; FALSE POSITIVE RESULT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MAXIMUM STANDARDIZED UPTAKE VALUE; OSTEOCHONDROMA; OSTEOCLASTOMA; OSTEOSARCOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOLOGICAL PARAMETERS; RECEIVER OPERATING CHARACTERISTIC; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CHILD; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; GIANT CELL TUMOR OF BONE; HEXOKINASE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84868149602     PISSN: 09368051     EISSN: 14343916     Source Type: Journal    
DOI: 10.1007/s00402-012-1588-2     Document Type: Article

References (49)

1. Kern KA, Brunetti A, Norton JA, Chang AE, Malawer M, Lack E et al (1988) Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 29:181-186 (Pubitemid 18056728)
2. Aoki J, Endo K, Watanabe H, Shinozaki T, Yanagawa T, Ahmed AR et al (2003) FDG-PET for evaluating musculoskeletal tumors: a review. J Orthop Sci 8:435-441 (Pubitemid 36702099)
3. Aoki J, Watanabe H, Shinozaki T, Takagishi K, Ishijima H, Oya N et al (2001) FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology 219: 774-777 (Pubitemid 32476270)
4. Feldman F, van Heertum R, Manos C (2003) 18FDG PET scanning of benign and malignant musculoskeletal lesions. Skeletal Radiol 32:201-208 (Pubitemid 36700858)
5. Charest M, Hickeson M, Lisbona R, Novales-Diaz JA, Derbekyan V, Turcotte RE (2009) FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases. Eur J Nucl Med Mol Imaging 36:1944-1951
6. Benz MR, Dry SM, Eilber FC, Allen-Auerbach MS, Tap WD, Elashoff D et al (2010) Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET. J Nucl Med 51:1174-1181
7. Folpe AL, Lyles RH, Sprouse JT, Conrad EU 3rd, Eary JF (2000) (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res. 6:1279-1287 (Pubitemid 30226209)
8. Eary JF, Conrad EU, Bruckner JD, Folpe A, Hunt KJ, Mankoff DA et al (1998) Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res 4:1215-1220 (Pubitemid 28213332)
9. Eftekhari F (2009) Imaging assessment of osteosarcoma in childhood and adolescence: diagnosis, staging, and evaluating response to chemotherapy. Cancer Treat Res 152:33-62
10. Cheon GJ, Kim MS, Lee JA, Lee SY, Cho WH, Song WS et al (2009) Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI. J Nucl Med 50:1435-1440
11. Dutour A, Decouvelaere AV, Monteil J, Duclos ME, Roualdes O, Rousseau R et al (2009) 18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model. J Nucl Med 50:1533-1540
12. Watanabe H, Shinozaki T, Yanagawa T, Aoki J, Tokunaga M, Inoue T et al (2000) Glucose metabolic analysis of musculoskeletal tumours using 18fluorine-FDG PET as an aid to preoperative planning. J Bone Joint Surg Br 82:760-767 (Pubitemid 30598763)
13. Hawkins DS, Conrad EU III, Butrynski JE, Schuetze SM, Eary JF (2009) [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer 115:3519-3525
14. Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Elashoff D et al (2009) FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res 15:2856-2863
15. Sato J, Yanagawa T, Dobashi Y, Yamaji T, Takagishi K, Watanabe H (2008) Prognostic significance of 18F-FDG uptake in primary osteosarcoma after but not before chemotherapy: a possible association with autocrine motility factor/phosphoglucose isomerase expression. Clin Exp Metastasis 25:427-435
16. Adler LP, Blair HF, Makley JT, Williams RP, Joyce MJ, Leisure G et al (1991) Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 32:1508-1512
17. Dehdashti F, Siegel BA, Griffeth LK, Fusselman MJ, Trask DD, McGuire AH et al (1996) Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2- deoxy-D-glucose. Radiology 200:243-247 (Pubitemid 26197368)
18. Aoki J, Watanabe H, Shinozaki T, Takagishi K, Tokunaga M, Koyama Y et al (2003) FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses. Skeletal Radiol 32:133-138 (Pubitemid 36818112)
19. Hamada K, Tomita Y, Qiu Y, Zhang B, Ueda T, Myoui A et al (2008) 18F-FDG-PET of musculoskeletal tumors: a correlation with the expression of glucose transporter 1 and hexokinase 2. Ann Nucl Med 22:699-705
20. Hamada K, Ueda T, Tomita Y, Higuchi I, Inoue A, Tamai N et al (2006) False positive 18F-FDG PET in an ischial chondroblastoma; an analysis of glucose transporter 1 and hexokinase II expression. Skeletal Radiol 35:306-310
21. Bischoff M, Bischoff G, Buck A, von Baer A, Pauls S, Scheffold F et al (2010) Integrated FDG-PET-CT: its role in the assessment of bone and soft tissue tumors. Arch Orthop Trauma Surg 130: 819-827
22. Mueckler M (1994) Facilitative glucose transporters. Eur J Biochem 219:713-725 (Pubitemid 24050938)
23. Bell GI, Kayano T, Buse JB, Burant CF, Takeda J, Lin D et al (1990) Molecular biology of mammalian glucose transporters. Diabetes Care 13:198-208 (Pubitemid 20092107)
24. Paudyal B, Oriuchi N, Paudyal P, Higuchi T, Nakajima T, Endo K (2008) Expression of glucose transporters and hexokinase II in cholangiocellular carcinoma compared using [18F]-2-fluro-2- deoxy-D-glucose positron emission tomography. Cancer Sci 99:260-266 (Pubitemid 351228478)
25. Fonteyne P, Casneuf V, Pauwels P, Van Damme N, Peeters M, Dierckx R et al (2009) Expression of hexokinases and glucose transporters in treated and untreated oesophageal adenocarcinoma. Histol Histopathol 24:971-977
26. Brown RS, Goodman TM, Zasadny KR, Greenson JK, Wahl RL (2002) Expression of hexokinase II and Glut-1 in untreated human breast cancer. Nucl Med Biol 29:443-453 (Pubitemid 34597116)
27. Campanacci M, Baldini N, Boriani S, Sudanese A (1987) J Bone Joint Surg Am 69:106-114
28. Reid R, Banerjee SS, Sciot R (2001) Giant cell tumor. In: Fletchcher CDM, Unni KK, Mertens F (eds) World Health Organization classification of tumors: pathology and genetics; tumors of soft tissue and bone. International Agency for Research on Cancer, Lyon, pp 310-312
29. Balke M, Schremper L, Gebert C, Ahrens H, Streitbuerger A, Koehler G et al (2008) Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol 134:969-978
30. Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH (2011) Recurrent giant cell tumor of long bones: analysis of surgical management. Clin Orthop Relat Res 469:1181-1187
31. Kivioja AH, Blomqvist C, Hietaniemi K, Trovik C, Walloe A, Bauer HC et al (2008) Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years. Acta Orthop 79:86-93 (Pubitemid 351271888)
32. Viswanathan S, Jambhekar NA (2010) Metastatic giant cell tumor of bone: are there associated factors and best treatment modalities? Clin Orthop Relat Res 468:827-833
33. Dominkus M, Ruggieri P, Bertoni F, Briccoli A, Picci P, Rocca M et al (2006) Histologically verified lung metastases in benign giant cell tumours - 14 cases from a single institution. Int Orthop 30:499-504 (Pubitemid 44900558)
34. Abdel-Nabi H, Doerr RJ, Lamonica DM, Cronin VR, Galantowicz PJ, Carbone GM et al (1998) Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose wholebody PET: correlation with histopathologic and CT findings. Radiology 206:755-760 (Pubitemid 28128526)
35. Fuster D, Duch J, Paredes P, Velasco M, Munoz M, Santamaría G et al (2008) Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/ computed tomography compared with conventional imaging procedures. J Clin Oncol 26:4746-4751
36. Christensen JD, Colby TV, Patz EF Jr. (2010) Correlation of [18F]-2-fluoro-deoxy-D-glucose positron emission tomography standard uptake values with the cellular composition of stage I nonsmall cell lung cancer. Cancer 116:4095-4102
37. Noguchi Y, Marat D, Saito A, Yoshikawa T, Doi C, Fukuzawa K et al (1999) Expression of facilitative glucose transporters in gastric tumors. Hepatogastroenterol 46:2683-2689 (Pubitemid 29454167)
38. Mamede M, Higashi T, Kitaichi M, Ishizu K, Ishimori T, Nakamoto Y et al (2005) [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia 7:369-379 (Pubitemid 40664226)
39. Paudyal B, Paudyal P, Oriuchi N, Tsushima Y, Nakajima T, Endo K (2008) Clinical implication of glucose transport and metabolism evaluated by 18F-FDG PET in hepatocellular carcinoma. Int J Oncol 33:1047-1054
40. Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT (1997) Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 80:1046-1051 (Pubitemid 27427603)
41. Ahrens WA, Ridenour RV 3rd, Caron BL, Miller DV, Folpe AL (2008) GLUT-1 expression in mesenchymal tumors: an immunohistochemical study of 247 soft tissue and bone neoplasms. Hum Pathol 39:1519-1526
42. Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Hasegawa T (2006) Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography. Eur J Nucl Med Mol Imaging 33:683-691 (Pubitemid 43846759)
43. Endo M, Tateishi U, Seki K, Yamaguchi U, Nakatani F, Kawai A et al (2007) Prognostic implications of glucose transporter protein- 1 (glut-1) overexpression in bone and soft-tissue sarcomas. Jpn J Clin Oncol 37:955-960 (Pubitemid 351176488)
44. Cifuentes M, García MA, Arrabal PM, Martínez F, Yanez MJ, Jara N et al (2011) Insulin regulates GLUT1-mediated glucose transport in MG-63 human osteosarcoma cells. J Cell Physiol 226:1425-1432
45. Robey RB, Hay N (2005) Mitochondrial hexokinases: guardians of the mitochondria. Cell Cycle 4:654-658 (Pubitemid 41353844)
46. Mathupala SP, Rempel A, Pedersen PL (1997) Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 29:339-343
47. Ito T, Noguchi Y, Satoh S, Hayashi H, Inayama Y, Kitamura H (1998) Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. Mod Pathol 11:437-443 (Pubitemid 28224445)
48. Shim HK, Lee WW, Park SY, Kim H, So Y, Kim SE (2009) Expressions of glucose transporter Types 1 and 3 and hexokinase- II in diffuse large B-cell lymphoma and other B-cell non-Hodgkin's lymphomas. Nucl Med Biol 36:191-197
49. Bakheet SM, Saleem M, Powe J, Al-Amro A, Larsson SG, Mahassin Z (2000) F-18 fluorodeoxyglucose chest uptake in lung inflammation and infection. Clin Nucl Med 25:273-278 (Pubitemid 30173877)